Primary Results from APOLLO-B Open-label Extension Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis
Anno:
2024
Introduction: The Phase 3, placebo-controlled APOLLO-B study (NCT03997383) is evaluating the efficacy and safety of patisiran in patients (pts) with ATTR cardiac amyloidosis in a 12-month (M) double-blind (DB) period followed by an open-label extension (OLE) period when all pts receive patisiran. During the DB period, patisiran demonstrated statistically…